International Scholarly Research Notices / 2013 / Article / Tab 1

Review Article

Platinum and Palladium Polyamine Complexes as Anticancer Agents: The Structural Factor

Table 1

Platinum anticancer agents with amine ligands.

CompoundCAS no. gMOADevelopment phaseToxicity

Cisplatin [17, 18, 21]15663-27-1Covalent binding short-range, intrastrandClinically approvedNephrotoxicity
Carboplatin [12, 303]41575-94-4Covalent binding short-range, intrastrandClinically approvedMyelosuppression reduced nephrotoxicity
Oxaliplatin [105107]61825-94-3Covalent binding short-range, intrastrandClinically approvedNeurotoxicity
Satraplatin [113, 114, 355]129580-63-8Covalent binding short-range, intrastrandPhase III clinical trialsMyelosuppression no significant oto-, neuro-, or nephrotoxicity
Picoplatin [114, 122124]181630-15-9Covalent binding short-range, intrastrandPhase III clinical trialsNeutropenia no neuro- or nephrotoxicity
BBR3464 [185]172903-00-3Covalent binding long-range, interstrand hPhase II clinical trialsNeutropenia anemia
aAH44 [186, 216]Non-covalent interaction electrostatic, H-bonding phosphate clamps
bTriplatinNC [186188]Non-covalent interaction electrostatic, H-bonding phosphate clamps
cLipoplatin [136]15663-27-1Covalent binding short-range, intrastrand controlled drug deliveryPhases II and III clinical trialsNegligible neuro- and nephrotoxicity
dLipoxal [141, 142]Covalent binding short-range, intrastrand controlled drug deliveryPhase I clinical trialsMild neutropenia no reno-, cardio-, or hepatotoxicity
eAroplatin [144]114488-24-3Covalent binding short-range, intrastrand controlled drug delivery iPhases I and II clinical trialsMyelosuppression mild nephrotoxicity
fProlindac [130]674289-90-8Covalent binding short-range, intrastrand controlled drug deliveryPhase II clinical trialsNegligible neurotoxicity

aComprising two (H2N(CH2)6NH2)2) groups substituting the leaving chlorides in BBR3464, n = 8+. bComprising two groups substituting the leaving chlorides in BBR3464, n = 6+. cLipoplatin: liposomal formulation of cisplatin; dLipoxal: liposomal formulation of oxaliplatin; eAroplatin: liposomal formulation of an oxaliplatin analogue. fNanopolymer-oxaliplatin conjugate. gMOA: mechanism of action. hDid not progress to Phase III, due to plasma decomposition and severe toxicity in Phase II human clinical trials. iDevelopment halted due to economic reasons.